AGC Biologics to Produce AAVantgarde’s Dual-Vector Gene Therapies
AGC Biologics and AAVantgarde Forge New Manufacturing Partnership to Advance Dual-Vector Gene Therapies for Inherited Retinal Diseases Following AAVantgarde Bio’s recent completion of a successful Series B financing round, the…
BeOne Medicines Highlights Advances in B-Cell Malignancy Treatments at ASH 2025
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase…
Quanterix Announces Strategic Board and Leadership Transitions to Accelerate Future Growth
Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection…
Contineum Therapeutics Releases Phase 2 RRMS Trial Results for PIPE-307
Contineum Therapeutics Reports Topline Data From Phase 2 VISTA Trial Evaluating PIPE-307 in Relapsing-Remitting Multiple Sclerosis Contineum Therapeutics, Inc. (NASDAQ: CTNM) (“Contineum” or the “Company”), a clinical-stage biopharmaceutical organization advancing…
Hercules Pharmaceuticals Joins Healthcare Distribution Alliance; Timothy Ward Appointed to Board
Hercules Pharmaceuticals Announces Membership in the Healthcare Distribution Alliance and Board Appointment of Timothy Ward Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution and a rapidly growing provider-aligned group…
ZIIHERA® + TEVIMBRA® Shows Strong Phase 3 Results in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Announces Positive Phase 3 HERIZON-GEA-01 Results Supporting ZIIHERA®-Based Regimens as Transformative First-Line Options for HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…
Oncolytics Biotech® Reaches FDA Agreement on Pivotal Trial Design for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech® Aligns with FDA on Pivotal Phase 3 Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy…
Tinostamustine Demonstrates Early Clinical Activity in Phase 1 Glioblastoma Study
Phase 1 Trial Reveals Promising Early Activity for Tinostamustine in Glioblastoma Purdue Pharma L.P. (“Purdue”) has announced encouraging preliminary data from its ongoing Phase 1 clinical study evaluating tinostamustine in…
Avenzo Therapeutics Names Scott Lipman as New Chief Financial Officer
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer, Strengthening Executive Leadership to Advance Next-Generation Oncology Pipeline Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology…
KaliVir, Roche Partner to Test VET3-TGI + Tecentriq® in Advanced Tumors
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company…
Boston Cell Standards Unveils Calibration Breakthrough to Enhance Accuracy in HER2-Low Breast Cancer Testing
Boston Cell Standards Announces Landmark CASI-01 Study in Lancet: eBioMedicine Demonstrating That Calibration Transforms Accuracy and Reproducibility in HER2-Low Breast Cancer Testing Boston Cell Standards today unveiled groundbreaking findings from…
Parse Biosciences Unveils FFPE-Compatible Single-Cell Barcoding Tech
Parse Biosciences Unveils Breakthrough FFPE-Compatible Barcoding Technology, Enabling Whole-Transcriptome Single-Cell Analysis from Archival Tissues Parse Biosciences, a global leader in scalable and accessible single-cell sequencing technologies, has announced a transformative…